# Study of MT1013 for the Treatment of Patients With Secondary Hyperparathyroidism

Study · id `cardio:ct-nct07122401` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07122401](<https://clinicaltrials.gov/study/NCT07122401>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07122401

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 424 participants.

## Technical summary

Registry record NCT07122401. Randomized; quadruple masking; primary purpose treatment. Start 2025-09-30 (actual); primary completion 2026-11-26 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 424 participants (planned count; ClinicalTrials.gov record NCT07122401, source copy `cardio:ctgov-nct07122401-2026-11-05`, retrieved 2026-11-18)
- Started: 2025-09-30 (actual) (ClinicalTrials.gov record NCT07122401, source copy `cardio:ctgov-nct07122401-2026-11-05`, retrieved 2026-11-18)
- Primary completion: 2026-11-26 (anticipated) (ClinicalTrials.gov record NCT07122401, source copy `cardio:ctgov-nct07122401-2026-11-05`, retrieved 2026-11-18)
- Completion: 2026-11-26 (anticipated) (ClinicalTrials.gov record NCT07122401, source copy `cardio:ctgov-nct07122401-2026-11-05`, retrieved 2026-11-18)
- Countries: China (ClinicalTrials.gov record NCT07122401, source copy `cardio:ctgov-nct07122401-2026-11-05`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07122401-2026-11-05`, retrieved 2026-11-18)

## The registry's words

- Brief title: Study of MT1013 for the Treatment of Patients With Secondary Hyperparathyroidism
- Condition: Secondary Hyperparathyroidism, Chronic Kidney Disease
- Intervention (Drug): MT1013
- Intervention (Drug): Cinacalcet
- Lead sponsor: Shaanxi Micot Pharmaceutical Technology Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)

## Provenance

Content hash: ee59b069a9c74bec48089e0e43ab413222f571c0d33e5e324c50b98d45c5b3c6
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
